Welcome to our dedicated page for Nymox Pharm news (Ticker: NYMXF), a resource for investors and traders seeking the latest updates and insights on Nymox Pharm stock.
Nymox Pharmaceutical Corporation (NYMXF) is a pharmaceutical preparation manufacturing company whose news flow centers on the development, regulatory review, and legal context surrounding its drug candidate NYMOZARFEX™ (Fexapotide). Company updates frequently describe progress and challenges in seeking approval to market NYMOZARFEX for benign prostatic hyperplasia (BPH) and for low grade localized prostate cancer.
News items from Nymox often highlight clinical data and long-term follow-up results. The company has reported 10-year follow-up data from its U.S. clinical trial of NYMOZARFEX for low grade localized prostate cancer, stating that the treatment produced important and statistically significant reductions in long-term cancer progression. Releases also describe the safety profile of NYMOZARFEX, with Nymox emphasizing the absence of side effects typically associated with existing BPH treatments.
Regulatory developments are another key theme in NYMXF news. Nymox has issued detailed updates on its marketing authorization applications to agencies such as the Danish Medicines Agency and the UK’s MHRA, including feedback, outstanding questions, and the need for re-submission where timelines expired. These communications provide insight into the regulatory review process for NYMOZARFEX and the company’s responses.
In addition, Nymox’s news coverage includes legal and corporate matters, such as litigation involving former executives, actions in courts in the United States and the Bahamas, and disputes with third parties. The company also reports on trading status and market tier changes for its stock, including its listing on the OTCQB Venture Market under the symbol NYMXF. Investors following NYMXF news can review these updates to understand the evolving clinical, regulatory, legal, and trading context for Nymox.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.